Ivan Ivanov1, Anton Matafonov, David Gailani. 1. aDepartment of Pathology, Microbiology and Immunology bDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA cDepartment of Bioengineering and Organic Chemistry, Tomsk Polytechnic University, Tomsk, Russia.
Abstract
PURPOSE OF REVIEW: Exposure of blood to foreign surfaces induces reciprocal conversion of the plasma proteins factor XII (fXII) and plasma prekallikrein (PPK) to the proteases α-fXIIa and α-kallikrein. This process, called contact activation, has a range of effects on host defence mechanisms, including promoting coagulation. The nature of the triggering mechanism for contact activation is debated. One hypothesis predicts that fXII has protease activity, either intrinsically or upon surface-binding, that initiates contact activation. We tested this by assessing the proteolytic activity of a recombinant fXII variant that cannot be converted to α-fXIIa. RECENT FINDINGS: The proteolytic activity of fXII-T (for 'triple' mutant), a variant with alanine substitutions for arginine at activation cleavage sites (Arg334, Arg344, and Arg353) was tested with known α-fXIIa substrates. FXII-T activates PPK in solution, and the reaction is enhanced by polyphosphate, an inducer of contact activation released from platelets. In the presence of polyphosphate, fXII-T converts fXII to α-fXIIa, and also converts the coagulation protein factor XI to its active form. SUMMARY: The findings support the hypothesis that contact activation is initiated through activity intrinsic to single-chain fXII, and indicate that preexisting α-fXIIa is not required for induction of contact activation.
PURPOSE OF REVIEW: Exposure of blood to foreign surfaces induces reciprocal conversion of the plasma proteins factor XII (fXII) and plasma prekallikrein (PPK) to the proteases α-fXIIa and α-kallikrein. This process, called contact activation, has a range of effects on host defence mechanisms, including promoting coagulation. The nature of the triggering mechanism for contact activation is debated. One hypothesis predicts that fXII has protease activity, either intrinsically or upon surface-binding, that initiates contact activation. We tested this by assessing the proteolytic activity of a recombinant fXII variant that cannot be converted to α-fXIIa. RECENT FINDINGS: The proteolytic activity of fXII-T (for 'triple' mutant), a variant with alanine substitutions for arginine at activation cleavage sites (Arg334, Arg344, and Arg353) was tested with known α-fXIIa substrates. FXII-T activates PPK in solution, and the reaction is enhanced by polyphosphate, an inducer of contact activation released from platelets. In the presence of polyphosphate, fXII-T converts fXII to α-fXIIa, and also converts the coagulation protein factor XI to its active form. SUMMARY: The findings support the hypothesis that contact activation is initiated through activity intrinsic to single-chain fXII, and indicate that preexisting α-fXIIa is not required for induction of contact activation.
Authors: Rainer Friedrich; Peter Panizzi; Pablo Fuentes-Prior; Klaus Richter; Ingrid Verhamme; Patricia J Anderson; Shun-Ichiro Kawabata; Robert Huber; Wolfram Bode; Paul E Bock Journal: Nature Date: 2003-10-02 Impact factor: 49.962
Authors: Ivan Ivanov; Ruhama Shakhawat; Mao-Fu Sun; S Kent Dickeson; Cristina Puy; Owen J T McCarty; Andras Gruber; Anton Matafonov; David Gailani Journal: Thromb Haemost Date: 2017-01-26 Impact factor: 5.249
Authors: Yasin Kokoye; Ivan Ivanov; Qiufang Cheng; Anton Matafonov; S Kent Dickeson; Shauna Mason; Daniel J Sexton; Thomas Renné; Keith McCrae; Edward P Feener; David Gailani Journal: Thromb Res Date: 2016-02-18 Impact factor: 3.944
Authors: Coen Maas; José W P Govers-Riemslag; Barend Bouma; Bettina Schiks; Bouke P C Hazenberg; Henk M Lokhorst; Per Hammarström; Hugo ten Cate; Philip G de Groot; Bonno N Bouma; Martijn F B G Gebbink Journal: J Clin Invest Date: 2008-09 Impact factor: 14.808
Authors: Linda Labberton; Ellinor Kenne; Andy T Long; Katrin F Nickel; Antonio Di Gennaro; Rachel A Rigg; James S Hernandez; Lynn Butler; Coen Maas; Evi X Stavrou; Thomas Renné Journal: Nat Commun Date: 2016-09-06 Impact factor: 14.919
Authors: Ivan Ivanov; Ingrid M Verhamme; Mao-Fu Sun; Bassem Mohammed; Qiufang Cheng; Anton Matafonov; S Kent Dickeson; Kusumam Joseph; Allen P Kaplan; David Gailani Journal: Blood Date: 2020-02-20 Impact factor: 25.476
Authors: Bassem M Mohammed; Qiufang Cheng; Anton Matafonov; Ingrid M Verhamme; Jonas Emsley; Keith R McCrae; Owen J T McCarty; Andras Gruber; David Gailani Journal: J Thromb Haemost Date: 2019-06-17 Impact factor: 16.036
Authors: Aleksandr Shamanaev; Ivan Ivanov; Mao-Fu Sun; Maxim Litvak; Priyanka Srivastava; Bassem M Mohammed; Rabia Shaban; Ashoka Maddur; Ingrid M Verhamme; Owen J T McCarty; Ruby H P Law; David Gailani Journal: Blood Adv Date: 2022-05-24
Authors: Ivan Ivanov; Anton Matafonov; Mao-Fu Sun; Bassem M Mohammed; Qiufang Cheng; S Kent Dickeson; Suman Kundu; Ingrid M Verhamme; Andras Gruber; Keith McCrae; David Gailani Journal: Blood Date: 2018-12-27 Impact factor: 25.476
Authors: Michael Wallisch; Christina U Lorentz; Hari H S Lakshmanan; Jennifer Johnson; Marschelle R Carris; Cristina Puy; David Gailani; Monica T Hinds; Owen J T McCarty; András Gruber; Erik I Tucker Journal: Res Pract Thromb Haemost Date: 2020-02-11